Rezolute (RZLT)

Executive Summary

Rezolute is a late-stage biopharmaceutical company singularly focused on developing ersodetug, a first-in-class monoclonal antibody designed as a universal treatment for hypoglycemia caused by all forms of hyperinsulinism (HI). The company addresses severe unmet needs in rare metabolic disorders, with its lead asset targeting congenital HI and tumor HI. Ersodetug's novel mechanism as an insulin receptor antagonist offers a potential paradigm shift for patients who currently lack effective medical therapies, often requiring invasive procedures like pancreatectomy. Rezolute is publicly traded (NASDAQ: RZLT) and has advanced ersodetug through Phase 2 proof-of-concept studies, demonstrating promising safety and efficacy. Rezolute is currently navigating the critical regulatory path for ersodetug following a Phase 3 trial in congenital HI (NCT06208215, estimated completion November 2027) and is concurrently advancing a parallel Phase 3 study in tumor HI (NCT06881992, estimated completion September 2027). The company has also explored RZ402 for diabetic macular edema, though its primary focus remains on the HI franchise. With no approved pharmacologic therapies for congenital HI beyond diazoxide, which has limitations, ersodetug has the potential to become the standard of care. Key upcoming catalysts include top-line data readouts from both Phase 3 trials, regulatory submissions, and potential partnerships.

Upcoming Catalysts (preview)

• Q2 2027Top-line Phase 3 data in congenital hyperinsulinism65% success
• Q3 2027Top-line Phase 3 data in tumor hyperinsulinism55% success
• Q4 2027FDA meeting or regulatory submission for congenital HI70% success